Literature DB >> 18268478

A new tumor-specific variant of GRP78 as target for antibody-based therapy.

Nicole Rauschert1, Stephanie Brändlein, Elisabeth Holzinger, Frank Hensel, Hans-Konrad Müller-Hermelink, H Peter Vollmers.   

Abstract

The chaperone GRP78 is a member of the heat-shock protein 70 (HSP70) family and is responsible for cellular homeostasis by preventing stress-induced apoptosis. GRP78 is expressed in all cells of the body. In malignant cells, which are permanently exposed to environmental stress, GRP78 is overexpressed and increased levels can be found in the cytoplasm and on the cell membrane. Thus, GRP78 promotes tumor proliferation, survival, metastases and resistance to a wide variety of therapies. Like other tumor-specific membrane molecules, GRP78 can also be present on cancer cells in a variant form. This modification qualifies it as a target for immune surveillance and antibody responses. The fully human monoclonal IgM antibody, SAM-6, was isolated from a gastric cancer patient and it binds to a new variant of GRP78 with a molecular weight of 82 kDa. The epitope is an O-linked carbohydrate moiety and is specific for malignant cells. These data show that cancer-specific modifications of cell-surface protection molecules are (a) subject of an immune response and (b) ideal targets for new therapeutical approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18268478     DOI: 10.1038/labinvest.2008.2

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  51 in total

Review 1.  Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Authors:  Srini V Kaveri; Gregg J Silverman; Jagadeesh Bayry
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

2.  Overexpression of TGF-ß 1 gene induces cell surface localized glucose-regulated protein 78-associated latency-associated peptide/TGF-ß.

Authors:  Takatoku Oida; Howard L Weiner
Journal:  J Immunol       Date:  2010-08-18       Impact factor: 5.422

3.  Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8).

Authors:  Catharina Steentoft; Katrine T Schjoldager; Emiliano Cló; Ulla Mandel; Steven B Levery; Johannes W Pedersen; Knud Jensen; Ola Blixt; Henrik Clausen
Journal:  Glycoconj J       Date:  2010-08-19       Impact factor: 2.916

Review 4.  Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential.

Authors:  Amy S Lee
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

5.  GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.

Authors:  Leo Rasche; Johannes Duell; Inês C Castro; Valentina Dubljevic; Manik Chatterjee; Stefan Knop; Frank Hensel; Andreas Rosenwald; Hermann Einsele; Max S Topp; Stephanie Brändlein
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

6.  Mining the O-glycoproteome using zinc-finger nuclease-glycoengineered SimpleCell lines.

Authors:  Catharina Steentoft; Sergey Y Vakhrushev; Malene B Vester-Christensen; Katrine T-B G Schjoldager; Yun Kong; Eric Paul Bennett; Ulla Mandel; Hans Wandall; Steven B Levery; Henrik Clausen
Journal:  Nat Methods       Date:  2011-10-09       Impact factor: 28.547

Review 7.  Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Authors:  Jens O Watzlawik; Bharath Wootla; Meghan M Painter; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2013-09       Impact factor: 4.618

8.  Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Authors:  Jami Mandelin; Marina Cardó-Vila; Wouter H P Driessen; Paul Mathew; Nora M Navone; Sue-Hwa Lin; Christopher J Logothetis; Anna Cecilia Rietz; Andrey S Dobroff; Bettina Proneth; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-11       Impact factor: 11.205

9.  Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis.

Authors:  Ren Liu; Xiuqing Li; Wenming Gao; Yue Zhou; Shiuan Wey; Satyajit K Mitra; Valery Krasnoperov; Dezheng Dong; Shuanglong Liu; Dan Li; Genyuan Zhu; Stan Louie; Peter S Conti; Zibo Li; Amy S Lee; Parkash S Gill
Journal:  Clin Cancer Res       Date:  2013-09-18       Impact factor: 12.531

10.  Regulation of PERK signaling and leukemic cell survival by a novel cytosolic isoform of the UPR regulator GRP78/BiP.

Authors:  Min Ni; Hui Zhou; Shiuan Wey; Peter Baumeister; Amy S Lee
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.